	US 11,702,464 B2
	Methods and composition for neutralization of influenza
Patrick Wilson, Chicago, IL (US); Yaoqing Chen, Chicago, IL (US); and Haley L. Dugan, Chicago, IL (US)
Assigned to The University of Chicago, Chicago, IL (US)
Appl. No. 16/977,327
Filed by The University of Chicago, Chicago, IL (US)
PCT Filed Mar. 1, 2019, PCT No. PCT/US2019/020223 § 371(c)(1), (2) Date Sep. 1, 2020, PCT Pub. No. WO2019/169231, PCT Pub. Date Sep. 6, 2019.
Claims priority of provisional application 62/637,508, filed on Mar. 2, 2018.
Prior Publication US 2021/0002354 A1, Jan. 7, 2021
Int. Cl. C07K 16/10 (2006.01); A61P 31/16 (2006.01); A61K 39/42 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/1018 (2013.01) [A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/16 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

10 Claims

1. An antibody or antibody fragment comprising:

a heavy chain variable region comprising a CDR1 of SEQ ID NO: 36, a CDR2 of SEQ ID NO: 38 and CDR3 of SEQ ID NO: 40, and a light chain variable region comprising a CDR1 of SEQ ID NO: 44, a CDR2 of SEQ ID NO: 46 and CDR3 of SEQ ID NO: 48 wherein the antibody or antibody fragment is capable of binding to influenza neuraminidase (NA) protein.